|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM259205826 |
| 003 |
DE-627 |
| 005 |
20231224190706.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.03.013
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0864.xml
|
| 035 |
|
|
|a (DE-627)NLM259205826
|
| 035 |
|
|
|a (NLM)27057998
|
| 035 |
|
|
|a (PII)S1521-6616(16)30041-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Berrón-Ruiz, Laura
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Impaired selective cytokine production by CD4(+) T cells in Common Variable Immunodeficiency associated with the absence of memory B cells
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.03.2017
|
| 500 |
|
|
|a Date Revised 19.11.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Common Variable Immunodeficiency (CVID) is a primary immunodeficiency characterized by B cell dysfunction and decreased serum immunoglobulin. CVID patients are classified by the absence or presence of memory B cells. In addition, T cell defects have been demonstrated in only a proportion of CVID patients. The aim of this study was to evaluate the function of CD4(+) T cells from CVID patients and its association with memory B cells. Patients were classified according to their Freiburg groups: group Ia and Ib, with decreased switched memory B cells (<0.4 of PBL), and group II, with normal B cell subsets. Their T cell function was evaluated after stimulation. We observed normal and even increased CD4(+) T cell proliferation in group Ia (p=0.0277). The proliferation positively correlated with the clinical severity score (r=0.4796). We observed lower levels of IL-17A and IL-10 in group Ia (p=0.0177, 0.0109) and Ib (p=0.0009, 0.0084) patients. Group Ib patients also had low levels of IL-13 and IL-9 (p=0.0169, 0.010). Group II patients had similar cytokine production to that of the controls. BAFFR expression was reduced in groups Ia (p=0.0001) and Ib (p=0.0002) and showed an inverse correlation with the severity score (p=0.0262; r=0.5371). ICOS expression was reduced in group Ia (p=0.0364), and PD-1 was increased in group Ib (p=0.0432) patients. This study shows a selective impairment in cytokine production in group Ia patients, which was more extensive than in group Ib patients. The impairment was associated with BAFFR expression in B cells, with ICOS and PD-1 in T cells and, remarkably, with the absence of memory B cells and with the disease severity. Our results suggest that the evaluation of cytokine expression by T cells in combination with the study of B cell memory could be important for understand the pathogenesis of CVID patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Activation
|
| 650 |
|
4 |
|a Co-stimulation
|
| 650 |
|
4 |
|a Common variable immunodeficiency
|
| 650 |
|
4 |
|a Cytokine
|
| 650 |
|
4 |
|a Memory B cells
|
| 650 |
|
4 |
|a T helper cells
|
| 650 |
|
7 |
|a B-Cell Activation Factor Receptor
|2 NLM
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD274 protein, human
|2 NLM
|
| 650 |
|
7 |
|a CTLA-4 Antigen
|2 NLM
|
| 650 |
|
7 |
|a ICOS protein, human
|2 NLM
|
| 650 |
|
7 |
|a IL10 protein, human
|2 NLM
|
| 650 |
|
7 |
|a IL13 protein, human
|2 NLM
|
| 650 |
|
7 |
|a IL17A protein, human
|2 NLM
|
| 650 |
|
7 |
|a IL9 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Inducible T-Cell Co-Stimulator Protein
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-13
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-17
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-9
|2 NLM
|
| 650 |
|
7 |
|a PDCD1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Programmed Cell Death 1 Receptor
|2 NLM
|
| 650 |
|
7 |
|a TNFRSF13C protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 700 |
1 |
|
|a López-Herrera, Gabriela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vargas-Hernández, Alexander
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Santos-Argumedo, Leopoldo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a López-Macías, Constantino
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Isibasi, Armando
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Segura-Méndez, Nora Hilda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bonifaz, Laura
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 166-167(2016) vom: 01. Mai, Seite 19-26
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:166-167
|g year:2016
|g day:01
|g month:05
|g pages:19-26
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.03.013
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 166-167
|j 2016
|b 01
|c 05
|h 19-26
|